396 related articles for article (PubMed ID: 28008867)
21. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.
Gubavu C; Prazuck T; Niang M; Buret J; Mille C; Guinard J; Avettand-Fènoël V; Hocqueloux L
J Antimicrob Chemother; 2016 Apr; 71(4):1046-50. PubMed ID: 26712907
[TBL] [Abstract][Full Text] [Related]
22. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
Elliot ER; Amara A; Pagani N; Else L; Moyle G; Schoolmeesters A; Higgs C; Khoo S; Boffito M
J Antimicrob Chemother; 2017 Jul; 72(7):2035-2041. PubMed ID: 28407075
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
[TBL] [Abstract][Full Text] [Related]
24. Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report.
Chiesi S; Rizzardo S; Piacentini D; Be G; Lattuada E; Tacconelli E; Lanzafame M
J Med Case Rep; 2019 Jul; 13(1):224. PubMed ID: 31331387
[TBL] [Abstract][Full Text] [Related]
25. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
Pialoux G; Marcelin AG; Cawston H; Guilmet C; Finkielsztejn L; Laurisse A; Aubin C
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):83-91. PubMed ID: 28741965
[TBL] [Abstract][Full Text] [Related]
27. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
[TBL] [Abstract][Full Text] [Related]
28. Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Allavena C; Volteau C; André-Garnier E; Guimard T; Hall N; Khatchatourian L; Morrier M; Billaud E; Rodallec A; Reliquet V; Jovelin T; Le Guen L; Perré P; Grégoire M; Raffi F
Med Mal Infect; 2019 Oct; 49(7):505-510. PubMed ID: 30583867
[TBL] [Abstract][Full Text] [Related]
29. [Safety profile of dolutegravir].
Rivero A; Domingo P
Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():9-13. PubMed ID: 25858606
[TBL] [Abstract][Full Text] [Related]
30. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
[TBL] [Abstract][Full Text] [Related]
31. Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
Mehta R; Wolstenholme A; Di Lullo K; Fu C; Joshi S; Crauwels H; Givens N; Vanveggel S; Wynne B; Adkison K
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987139
[TBL] [Abstract][Full Text] [Related]
32. Barrier to Resistance of Dolutegravir in Two-Drug Combinations.
Yoshinaga T; Miki S; Kawauchi-Miki S; Seki T; Fujiwara T
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602514
[TBL] [Abstract][Full Text] [Related]
33. Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.
Dailly E; Allavena C; Grégoire M; Reliquet V; Bouquié R; Billaud E; Hernando H; Bouchez S; Deslandes G; Hall N; Jolliet P; Raffi F
J Antimicrob Chemother; 2015 Dec; 70(12):3307-10. PubMed ID: 26271944
[TBL] [Abstract][Full Text] [Related]
34. Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring.
Simonetti FR; Cattaneo D; Zanchetta N; Giacomet V; Micheli V; Ciminera N; Gervasoni C
Antivir Ther; 2017; 22(4):361-363. PubMed ID: 28051809
[TBL] [Abstract][Full Text] [Related]
35. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
Rathbun RC; Lockhart SM; Miller MM; Liedtke MD
Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658
[TBL] [Abstract][Full Text] [Related]
36. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
[TBL] [Abstract][Full Text] [Related]
37. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
[TBL] [Abstract][Full Text] [Related]
38. Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.
Yamada E; Takagi R; Tanabe Y; Fujiwara H; Hasegawa N; Kato S
Int J Clin Pharmacol Ther; 2017 Jul; 55(7):567-570. PubMed ID: 28427498
[TBL] [Abstract][Full Text] [Related]
39. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR
Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622
[TBL] [Abstract][Full Text] [Related]
40. Dolutegravir, abacavir and lamivudine as HIV therapy.
Fernandez-Montero JV; Barreiro P; Labarga P; De Mendoza C; Soriano V
Expert Opin Pharmacother; 2014 May; 15(7):1051-7. PubMed ID: 24754315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
